AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8218758 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 60
Study 8218758 — intervention group
Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 60
Study 3578422 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 U sodium heparin
Number of subjects: 24
Study 3578422 — intervention group
Group type: EXPERIMENTAL
Intervention: 7500 U sodium heparin
Number of subjects: 24
Study 3578422 — intervention group
Group type: EXPERIMENTAL
Intervention: 10000 U sodium heparin
Number of subjects: 24
Study 3578422 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin neutralization activity
Number of subjects: 24
Study 3578422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinopeptide A
Number of subjects: 24
Study 29125719 — intervention group
Group type: EXPERIMENTAL
Intervention: Obiltoxaximab 4 mg/kg
Number of subjects: 0
Study 29125719 — intervention group
Group type: EXPERIMENTAL
Intervention: Obiltoxaximab 8 mg/kg
Number of subjects: 0
Study 29125719 — intervention group
Group type: EXPERIMENTAL
Intervention: Obiltoxaximab 16 mg/kg
Number of subjects: 0
Study 29125719 — intervention group
Group type: EXPERIMENTAL
Intervention: Obiltoxaximab 20 mg/kg
Number of subjects: 0
Study 29125719 — intervention group
Group type: EXPERIMENTAL
Intervention: Obiltoxaximab 24 mg/kg
Number of subjects: 0
Study 29125719 — intervention group
Group type: EXPERIMENTAL
Intervention: Obiltoxaximab (all doses)
Number of subjects: 0
Study 27537996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 0
Study 27537996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 0
Study 27537996 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 0
Study 27537996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27537996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (both IXEQ2W and IXEQ4W)
Number of subjects: 0
Study 27537996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 24439682 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioural treatment
Number of subjects: 168
Study 24439682 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural treatment
Number of subjects: 168
Study 24439682 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual improved with Smith's norms
Number of subjects: 168
Study 23275372 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape polyphenols (PPs) 2 g/day
Number of subjects: 38
Study 23275372 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 38
Study 21645041 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (self-selected soothing music for 30 minutes)
Number of subjects: 54
Study 21645041 — intervention group
Group type: COMPARATOR
Intervention: Chair rest (quiet sitting for 30 minutes)
Number of subjects: 54
Study 17932377 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle-filtered air
Number of subjects: 21
Study 17932377 — intervention group
Group type: COMPARATOR
Intervention: Nonfiltered air
Number of subjects: 21
Study 16814663 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone
Number of subjects: 30
Study 16814663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12636461 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR first with 3 minutes of basic CPR prior to defibrillation (n = 104)
Number of subjects: 200
Study 12636461 — intervention group
Group type: COMPARATOR
Intervention: Standard care with immediate defibrillation (n = 96)
Number of subjects: 200
Study 12636461 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR first with 3 minutes of basic CPR prior to defibrillation (n = 64, response times longer than 5 minutes)
Number of subjects: 200
Study 12636461 — intervention group
Group type: COMPARATOR
Intervention: Standard care with immediate defibrillation (n = 55, response times longer than 5 minutes)
Number of subjects: 200
Study 12636461 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR first with 3 minutes of basic CPR prior to defibrillation (n = 40, response times up to 5 minutes)
Number of subjects: 200
Study 12636461 — intervention group
Group type: COMPARATOR
Intervention: Standard care with immediate defibrillation (n = 41, response times up to 5 minutes)
Number of subjects: 200
Study 10758987 — intervention group
Group type: EXPERIMENTAL
Intervention: Original images
Number of subjects: 71
Study 10758987 — intervention group
Group type: COMPARATOR
Intervention: Compression ratio 6:1
Number of subjects: 71
Study 10758987 — intervention group
Group type: COMPARATOR
Intervention: Compression ratio 10:1
Number of subjects: 71
Study 10758987 — intervention group
Group type: COMPARATOR
Intervention: Compression ratio 16:1
Number of subjects: 71
Study 8716494 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal grid pattern intervention using black insulation tapes
Number of subjects: 10
Study 8716494 — intervention group
Group type: COMPARATOR
Intervention: Control group (other types of dementia)
Number of subjects: 10
Study 1306606 — intervention group
Group type: EXPERIMENTAL
Intervention: SpermPrep filtration method
Number of subjects: 148
Study 1306606 — intervention group
Group type: COMPARATOR
Intervention: Double sperm wash (SW) procedure
Number of subjects: 148
Study 3948092 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic Villus Sampling (CVS)
Number of subjects: 202
Study 3948092 — intervention group
Group type: COMPARATOR
Intervention: Control (no CVS)
Number of subjects: 202
Study 30457230 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP group
Number of subjects: 54
Study 30457230 — intervention group
Group type: COMPARATOR
Intervention: HA group
Number of subjects: 54
Study 26689304 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative cognitive‐affective therapy for BN (ICAT‐BN)
Number of subjects: 80
Study 26689304 — intervention group
Group type: COMPARATOR
Intervention: Enhanced cognitive behavior therapy (CBT‐E)
Number of subjects: 80
Study 26689304 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 80
Study 25485197 — intervention group
Group type: EXPERIMENTAL
Intervention: Borage and echium seed oils
Number of subjects: 28
Study 23000708 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium‐incorporated titanium implants
Number of subjects: 60
Study 23000708 — intervention group
Group type: COMPARATOR
Intervention: Control titanium implants
Number of subjects: 60
Study 20496965 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized disability-specific abuse assessment intervention at Time 1 (T1) and Time 2 (T2)
Number of subjects: 0
Study 20496965 — intervention group
Group type: COMPARATOR
Intervention: Control group completing the assessment intervention at Time 2 (T2)
Number of subjects: 0
Study 20496965 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized disability-specific abuse assessment intervention
Number of subjects: 0
Study 17038684 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-sulfamethoxypyrazine-pyrimethamine
Number of subjects: 606
Study 17038684 — intervention group
Group type: COMPARATOR
Intervention: artemether-lumefantrine
Number of subjects: 606
Study 14610474 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled nitric oxide (eNO) measurement
Number of subjects: 0
Study 14610474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rank regression analysis
Number of subjects: 0
Study 10910838 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg/kg
Number of subjects: 63
Study 10910838 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg/kg
Number of subjects: 63
Study 10910838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 8718563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (1 mg single dose at the end of HD session)
Number of subjects: 0
Study 8718563 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment period (control)
Number of subjects: 0
Study 8718563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0
Study 1572445 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM injections
Number of subjects: 18
Study 1572445 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 18
Study 3917653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin (30 mg/day) and FT‐207 (0.6 g/day p.o.) after 1/2MF'C regimen (mitomycin C 2 mg and cytosine arabinoside 20 mg i.v. twice a week for 3 weeks, FT‐207 400 mg/day i.v. for 3 weeks)
Number of subjects: 162
Study 3917653 — intervention group
Group type: COMPARATOR
Intervention: FT‐207 alone after 1/2MF'C regimen
Number of subjects: 162
Study 3917653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin
Number of subjects: 162
Study 31691253 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroSENSE EEG monitor
Number of subjects: 75
Study 31566694 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) plus usual obstetric care
Number of subjects: 400
Study 31566694 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound treatment plus usual obstetric care
Number of subjects: 400
Study 31566694 — intervention group
Group type: COMPARATOR
Intervention: Usual obstetric care only
Number of subjects: 400
Study 28919733 — intervention group
Group type: EXPERIMENTAL
Intervention: CET + IMT
Number of subjects: 81
Study 28919733 — intervention group
Group type: EXPERIMENTAL
Intervention: CET
Number of subjects: 81
Study 28919733 — intervention group
Group type: COMPARATOR
Intervention: Control (free walking)
Number of subjects: 81
Study 25882973 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia ceramic cantilever fixed dental prostheses (ZC-CFDPs)
Number of subjects: 21
Study 25882973 — intervention group
Group type: COMPARATOR
Intervention: Metal ceramic cantilever fixed dental prostheses (MC-CFDPs)
Number of subjects: 21
Study 25882973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ZC-CFDPs and MC-CFDPs
Number of subjects: 21
Study 24273968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Yijing Decoction (BYD), tamoxifen tablet (TT), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Number of subjects: 450
Study 24273968 — intervention group
Group type: COMPARATOR
Intervention: Bushen Yijing Decoction (BYD), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Number of subjects: 450
Study 24273968 — intervention group
Group type: COMPARATOR
Intervention: tamoxifen tablet (TT), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Number of subjects: 450
Study 24273968 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 450
Study 24273968 — intervention group
Group type: COMPARATOR
Intervention: Control group 1
Number of subjects: 450
Study 24273968 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group and control group 1
Number of subjects: 450
Study 22102213 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis ZCB00
Number of subjects: 22
Study 22102213 — intervention group
Group type: COMPARATOR
Intervention: Acrysof SN60WF
Number of subjects: 22
Study 19393261 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level random-dot kinematograms (RDKs)
Number of subjects: 0
Study 19393261 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level random-dot kinematograms (RDKs)
Number of subjects: 0
Study 16839836 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% lipid/heparin infusion at a rate of 1.5 mL/min for 6 hours
Number of subjects: 8
Study 16839836 — intervention group
Group type: COMPARATOR
Intervention: Saline/heparin infusion at a rate of 1.5 mL/min for 6 hours
Number of subjects: 8
Study 12632618 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 50
Study 12632618 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 50
Study 10706957 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicomponent acellular vaccine (pertussis toxin and filamentous hemagglutinin)
Number of subjects: 0
Study 10706957 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocomponent acellular vaccine (pertactin)
Number of subjects: 0
Study 10706957 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no vaccination)
Number of subjects: 0
Study 9305674 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin alone for 24 to 48 weeks
Number of subjects: 150
Study 9305674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin combined with alpha interferon (3 million units three times weekly for 6 months)
Number of subjects: 150
Study 9305674 — intervention group
Group type: COMPARATOR
Intervention: Alpha interferon alone
Number of subjects: 150
Study 1588426 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment
Number of subjects: 168
Study 1588426 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study 3904040 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasix
Number of subjects: 12
Study 3904040 — intervention group
Group type: COMPARATOR
Intervention: Aquasin
Number of subjects: 12
Study 3904040 — intervention group
Group type: COMPARATOR
Intervention: Puresis
Number of subjects: 12
Study 3904040 — intervention group
Group type: COMPARATOR
Intervention: Furetic
Number of subjects: 12
Study 29253747 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/kg/d of methylprednisolone (group T1, n=17)
Number of subjects: 51
Study 29253747 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/kg/d of methylprednisolone at consent and 100 mg/2 h until kidney harvest (group T2, n=17)
Number of subjects: 51
Study 29253747 — intervention group
Group type: COMPARATOR
Intervention: Normal donors as controls (n=17)
Number of subjects: 51
Study 29253747 — intervention group
Group type: COMPARATOR
Intervention: Kidney recipients from group T1
Number of subjects: 51
Study 29092730 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel generic 75 mg
Number of subjects: 20
Study 29092730 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel reference 75 mg
Number of subjects: 20
Study 26651616 — intervention group
Group type: EXPERIMENTAL
Intervention: Game (serious game format)
Number of subjects: 182
Study 26651616 — intervention group
Group type: COMPARATOR
Intervention: Control (non-interactive webpage)
Number of subjects: 182
Study 23447407 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF alone for 72 weeks
Number of subjects: 40
Study 23447407 — intervention group
Group type: COMPARATOR
Intervention: FTC/TDF plus HBIG for 72 weeks
Number of subjects: 40
Study 21034301 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-related pictures
Number of subjects: 63
Study 21034301 — intervention group
Group type: COMPARATOR
Intervention: Neutral pictures
Number of subjects: 63
Study 18706802 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine with sufentanil 5 microg
Number of subjects: 78
Study 18706802 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine with clonidine 75 microg
Number of subjects: 78
Study 18706802 — intervention group
Group type: COMPARATOR
Intervention: plain ropivacaine
Number of subjects: 78
Study 16539572 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement intervention (4 sessions)
Number of subjects: 51
Study 16539572 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 51
Study 12752561 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural sway measurement using Balance Master Pro(R)
Number of subjects: 195
Study 12752561 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural sway measurement with respect to body weight and alcohol consumption
Number of subjects: 195
Study 10578207 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP; 25 E% protein)
Number of subjects: 65
Study 10578207 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (LP; 12 E% protein)
Number of subjects: 65
Study 8566257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized E2
Number of subjects: 27
Study 8566257 — intervention group
Group type: COMPARATOR
Intervention: Transdermal E2
Number of subjects: 27
Study 1662191 — intervention group
Group type: EXPERIMENTAL
Intervention: ITRA-PEL (2 x 100 mg once daily)
Number of subjects: 8
Study 1662191 — intervention group
Group type: EXPERIMENTAL
Intervention: ITRA-PEG (4 x 50 mg once daily)
Number of subjects: 8
Study 1662191 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ITRA-PEL and ITRA-PEG
Number of subjects: 8
Study 7102528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg
Number of subjects: 15
Study 7102528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 15
Study 7102528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 20 mg
Number of subjects: 15
Study 7102528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31356432 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (ABO) 50 Units
Number of subjects: 300
Study 31356432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 30520216 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey/guar preload (150 mL containing 17 g whey protein plus 5 g guar)
Number of subjects: 79
Study 30520216 — intervention group
Group type: COMPARATOR
Intervention: Placebo preload
Number of subjects: 79
Study 26598291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV)
Number of subjects: 400
Study 26598291 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal corporal punishment/physical violence
Number of subjects: 400
Study 26598291 — intervention group
Group type: COMPARATOR
Intervention: Maternal depression and attitudes about corporal punishment
Number of subjects: 400
Study 26598291 — intervention group
Group type: COMPARATOR
Intervention: Non-use of corporal punishment/physical violence
Number of subjects: 400
Study 27129183 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg followed by 0.5 mg 1 hour later)
Number of subjects: 21
Study 27129183 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 21
Study 24472156 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) dispersible
Number of subjects: 454
Study 24472156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) paediatric tablets
Number of subjects: 454
Study 22948132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.25mg for 8 days from the day of HCG administration
Number of subjects: 200
Study 22948132 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 200
Study 20718766 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hPRL (60 μg/kg) administered subcutaneously every 12 h for 28 days (Study 1)
Number of subjects: 16
Study 20718766 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hPRL (60 μg/kg) administered every 12 h for 7 days (Study 2)
Number of subjects: 16
Study 20718766 — intervention group
Group type: COMPARATOR
Intervention: r-hPRL (60 μg/kg) administered daily for 7 days (Study 2)
Number of subjects: 16
Study 20718766 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 7 days (Study 2)
Number of subjects: 16
Study 20718766 — intervention group
Group type: COMPARATOR
Intervention: r-hPRL alternating with placebo every 12 h for 7 days (Study 2)
Number of subjects: 16
Study 17951067 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d curcumin
Number of subjects: 36
Study 17951067 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/d curcumin
Number of subjects: 36
Study 17951067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15664003 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone (MK-4) 45 mg, ergocalciferol (vitamin D2) 1000 IU, calcium 600 mg daily for 2 years
Number of subjects: 200
Study 15664003 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no intervention)
Number of subjects: 200
Study 14717246 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning nouns in the context of novel, moving objects
Number of subjects: 72
Study 14717246 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning verbs
Number of subjects: 72
Study 14717246 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar objects for child verb learners
Number of subjects: 72
Study 14717246 — intervention group
Group type: COMPARATOR
Intervention: Adults (N = 20) learning verbs
Number of subjects: 72
Study 10067809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet
Number of subjects: 0
Study 10067809 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10067809 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in total or saturated fat intake or cholesterol intake
Number of subjects: 0
Study 10067809 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in dietary cholesterol intake
Number of subjects: 0
Study 10067809 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in saturated fat intake
Number of subjects: 0
Study 7726651 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg gemeprost (Cergem)
Number of subjects: 87
Study 7726651 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical termination of pregnancy by cervical dilatation and curettage
Number of subjects: 87
Study 2024813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/day for 3 days)
Number of subjects: 17
Study 2024813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6788167 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback group receiving training in relaxation and management of stress
Number of subjects: 204
Study 6788167 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving simple health education literature
Number of subjects: 204
Study 31133577 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE+support as usual
Number of subjects: 0
Study 31133577 — intervention group
Group type: COMPARATOR
Intervention: Support as usual alone
Number of subjects: 0
Study 28132019 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 21596
Study 28132019 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no vaccination)
Number of subjects: 21596
Study 24942311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide supplementation
Number of subjects: 30